News | August 08, 2025
Caplin Point Laboratories posts Q1 FY26 consolidated PAT at Rs. 152.80 Cr
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
This is the group’s first NoC approval in Canada
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Cenexi reports an EBITDA breakeven for the quarter
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Athena is also exploring the use of this technology for expanded carrier screening
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Vasograin Plus represents a major advancement in the treatment of migraine
Subscribe To Our Newsletter & Stay Updated
